Method for quantifying lipopolysaccharide binding protein

• US 5,484,705 A
• Filed: 01/24/1994
• Issued: 01/16/1996
• Est. Priority Date: 01/24/1994
• Status: Expired due to Term

• Current Assignee: Xoma Corp.
• Original Assignee: Xoma Corp.
• Inventors: Ma, Jeremy K., White, Mark L., Carroll, Stephen F.
• Primary Examiner(s): Scheiner, Toni R.
• Assistant Examiner(s): DUFFY, PATRICIA ANN
• Application Number:
  US08/186,811
• Time in Patent Office: 722 Days
• Field of Search: 435/7.32, 435/7.9, 435/7.92-7.95, 435/7.5, 436/501, 436/811
• US Class Current: 435/7.32
• CPC Class Codes: G01N 33/56911 Bacteria
• CPC Class Codes: G01N 33/68 involving proteins, peptides or amino acids involving lipoproteins G01N33/92
• CPC Class Codes: Y10S 436/811 Test for named disease, body condition or organ function
• CPC Class Codes: Y10S 436/815 Test for named compound or class of compounds
• CPC Class Codes: Y10S 436/821 involving complement factors or complement systems

Abstract

The present invention provides a method for quantifying the presence of extracellular LBP in body fluids including blood in a subject comprising conducting an LBP immunoassay on plasma obtained from said subject.

Claims

1. A method for screening for gram-negative bacterial endotoxin involvement in an acute phase response in humans comprising:

(a) contacting a blood sample from a subject exhibiting an acute phase response with a specific binding partner for lipopolysaccharide binding protein,

(b) determining the level of lipopolysaccharide binding protein in said blood sample, and

(c) comparing the level of lipopolysaccharide binding protein determined in step (b) to levels of lipopolysaccharide binding protein in blood circulation in normal subjects, elevated levels of lipopolysaccharide binding protein being indicative of an acute phase response involving gram-negative bacterial endotoxin.

2. The method of claim 1 wherein the acute phase response is associated with sepsis.